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MARCKS is a widely expressed protein kinase C substrate that is essential for normal prenatal development of the central
nervous system in mice. MARCKS-deficient mice exhibit universal perinatal mortality and numerous developmental abnor-
malities of the brain and retina. To determine which domains of the protein were important in complementing these
neurodevelopmental anomalies, we have interbred MARCKS knockout mice with transgenic mice expressing an epitope-tagged
human MARCKS transgene that can completely correct the MARCKS-deficient phenotype. Previous structure–function studies
showed that a nonmyristoylatable form of MARCKS could correct all of the neuroanatomical abnormalities, and resulted in
approximately 25% viable pups that grew to adulthood and were fertile. The present experiment attempted a similar
complementation strategy in which a nonmyristoylatable, ‘‘pseudo-phosphorylated’’ form of the protein was used, which has
been shown to be almost completely cytosolic in cell expression studies. Surprisingly, this transgene was able to complement
almost all of the cerebral anatomical abnormalities characteristic of the knockout mice. However, these mice also exhibited a
universal, novel phenotype: profound retinal ectopia, in which retinal tissue was often found in the vitreous humor as well as
extraocularly. Retrospective evaluation of the original MARCKS knockout phenotype revealed that this anomaly was present in
about 43% of the knockout mice, and was clearly detectable as early as embryonic day 12.5, before retinal cell differentiation
begins. These data suggest that a nonmyristoylatable, pseudo-phosphorylated form of MARCKS can complement most if not all
cerebral aspects of the MARCKS-deficient phenotype, but that it appears to worsen a retinal phenotype, perhaps by exerting a
dominant-negative effect on a coexpressed MARCKS homologue. © 1998 Academic Press
INTRODUCTION
The myristoylated alanine-rich C kinase substrate
(MARCKS), a prominent cellular substrate of protein kinase
C (PKC), is an acidic, heat-stable protein with three highly
conserved domains: a myristoylation consensus sequence
following the glycine residue at position 2 in the amino
terminus; the site of intron splicing; and the phosphoryla-
tion site domain (PSD), which contains three or four serines
that are the only residues known to be phosphorylated by
PKC (reviewed in Aderem, 1992; Blackshear, 1993). The
PSD has been shown to interact with calmodulin (Graff et
al., 1989; McIlroy et al., 1991), actin (Hartwig et al., 1992),
cathepsin B (Spizz and Blackshear, 1997), and cellular mem-
branes (Kim et al., 1994a,b; Swierczynski and Blackshear,
1995, 1996); in all cases, these interactions are inhibited by
phosphorylation of MARCKS by PKC. Although the exact
function of MARCKS in cells has not been determined,
previous studies in cell-free systems, intact cells and intact
animals have implicated both the PSD and the amino
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terminal myristate moiety in the plasma membrane asso-
ciation of the protein (Kim et al., 1994a,b; Swierczynski and
Blackshear, 1995, 1996; Swierczynski et al., 1996).
Studies in mice in which the gene encoding MARCKS
(Macs) was disrupted showed that MARCKS expression was
essential for the normal development of the central nervous
system and postnatal survival (Stumpo et al., 1995; Black-
shear et al., 1996, 1997). These mice exhibited several gross
abnormalities of the central nervous system, including
failure of fusion of the cerebral hemispheres, agenesis of the
corpus callosum and other forebrain commissures, defects
in cortical and retinal lamination, and neuronal leptomen-
ingeal ectopia, as well as high frequencies of exencephaly.
More recently, we have shown that these anatomical de-
fects could be completely complemented by the transgenic
expression of epitope-tagged human MARCKS, driven by
3.4 kb of human MACS promoter, in the Macs (2/2) mice
(Swierczynski et al., 1996). We also showed that the trans-
genic expression of a nonmyristoylated form of human
MARCKS, in which the glycine in the 2 position was
mutated to an alanine (A2/G2 mutation), surprisingly re-
sulted in the apparent correction of all of the anatomical
defects characteristic of the Macs (2/2) mice and resulted
in a 25% postnatal survival rate (Swierczynski et al., 1996).
The purpose of the present studies was to further inves-
tigate this ‘‘structure–function’’ paradigm by attempting to
rescue the Macs (2/2) mice with a transgene consisting of
the identical human MACS gene to those described above,
except that the amino terminal glycine was mutated to
alanine (A2/G2), preventing myristoylation, and the four
serines in the PSD were mutated to aspartic acid residues
(D/S), to electrostatically mimic the maximally phosphor-
ylated state of the protein. In contrast to the wild-type
protein, or MARCKS in which either but not both of these
mutations was present, this ‘‘double-mutant’’ MARCKS
was almost exclusively cytosolic in intact cell studies
(Swierczynski and Blackshear, 1996), and exhibited much
weaker affinity for cellular membranes in cell-free assays
(Swierczynski and Blackshear, 1995). We show here that,
although all of the Macs (2/2) mice expressing the double-
mutant transgene died in the perinatal period, surprisingly,
all of the known anatomical defects seen in the brains of the
knockout mice were corrected. However, we also noted the
appearance of a novel phenotype in 100% of the knockout
mice expressing the double-mutant transgene, in which
retinal tissue was ectopically located in the vitreous humor
and elsewhere. This abnormality was found in about 43% of
the Macs (2/2) mice without a transgene. These data
suggest that a ‘‘pseudo-phosphorylated,’’ nonmyristoylated
form of MARCKS, which has a much lower than normal
affinity for cellular membranes, may simultaneously cor-
rect some of the anatomical defects of the Macs (2/2)
phenotype while worsening others, perhaps through a
dominant negative effect on a normally expressed
MARCKS homologue, the MARCKS-like protein (MLP).
MATERIALS AND METHODS
Construction of Transgenic Vector
MACS(A2/G2)D/S-12CA5
The starting clone for this mutant transgenic vector was the
plasmid MACS(A2/G2)-12CA5 (Swierczynski et al., 1996). This
7.5-kb insert in Bluescribe (Stratagene, La Jolla, CA) contains a
portion of the originally described human gene encoding MARCKS
(MACS; Harlan et al., 1991) consisting of about 3.4 kb of the MACS
59-flanking region, the entire coding region and single intron, and
0.6 kb of 39-flanking region. The native human MARCKS protein
coding sequence had been modified to contain a nine-amino-acid
epitope tag derived from influenza virus hemagglutinin (Kolodjiej
and Young, 1991), inserted five amino acids from the carboxyl
terminus; this epitope-tagged human construct has been shown to
completely complement the MARCKS-deficiency phenotype in
mice (Swierczynski et al., 1996). In addition, the amino terminal
glycine (G2) had been mutated to alanine (A2) to prevent cotrans-
lational myristoylation.
For the current study, this parent plasmid was further modified
so that the four serines in the phosphorylation site domain (Black-
shear, 1993) were mutated to aspartic acid residues, in order to
mimic electrostatically the fully phosphorylated state of the pro-
tein (pseudo-phosphorylated MARCKS). This was carried out using
the Altered Sites oligonucleotide-directed in vitro mutagenesis kit
from Promega (Madison, WI). Correctly mutated sequences were
confirmed by dideoxy sequencing (Sanger et al., 1977). This double
mutant, (A2/G2) D/S, has been shown previously to be almost
completely cytosolic in cell-free systems and in intact cells, in
contrast to the plasma membrane association of most of the
wild-type protein (Swierczynski and Blackshear, 1995, 1996). All
other methods, including the generation and characterization of
the transgenic mice, including the MARCKS- and MLP-b-
galactosidase-expressing mice, interbreeding with Macs (2/2)
mice, subcellular fractionation, routine histology, immunohisto-
chemistry, and routine Northern, Southern, and Western blotting,
were performed as described previously (Swierczynski et al., 1996;
Blackshear et al., 1997; Stumpo et al., 1998).
RESULTS
Subcellular Distribution of the Double Mutant
MARCKS Protein
Three lines of transgenic mice expressing the vector
MACS(A2/G2)D/S-12CA5 (hereafter known as the ‘‘double-
mutant’’), were evaluated by Southern, Northern, and West-
ern blotting of various tissues, and one line with high-level
expression of the mutant protein was chosen for interbreed-
ing with the Macs (1/2) mice. The level of expression of
the transgenic MARCKS protein in the transgenic Macs
(1/1) mice was approximately 2.2-fold that of the endoge-
nous protein in the brains of these mice, as determined by
quantitative Western blotting of brain homogenates from
three mice with an antibody directed at the highly con-
served amino terminal peptide of the protein (Lobaugh and
Blackshear, 1990; not shown). No abnormalities were noted
in these transgenic mice, in size, weight, breeding behavior,
or gross morphology of tissues and detailed histology of
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brain and retina. When brains of adult mice from this line
were evaluated for subcellular distribution of the mutant
MARCKS protein and compared to brains from a similar
line of mice expressing the epitope-tagged, wild-type hu-
man protein, 45 6 13% (mean 6 SD) of double-mutant
MARCKS was present in the high-speed supernatant or
cytosolic fraction, compared to only 8 6 1% of the wild-
type protein (P 5 0.004 using Student’s t test; n 5 3 in each
group). Similar results were observed with the endogenous
mouse protein (not shown).
The subcellular distribution of the double-mutant pro-
tein was also analyzed by immunohistochemistry of the
developing neural tube at E9.5, when it is possible to see the
plasma membrane distribution of wild-type MARCKS by
staining for either the native protein or the epitope-tagged
transgene (Swierczynski et al., 1996; Blackshear et al.,
1996). As shown in Fig. 1, the wild-type epitope-tagged
protein was almost exclusively associated with the plasma
membrane under these conditions. The double-mutant pro-
tein was also membrane-associated to a large extent, but its
distribution appeared to be greater in the cytosol than that
of the wild-type protein. Parallel immunostaining of an
E9.5 mouse embryo not expressing an epitope-tagged ver-
sion of MARCKS gave no visible staining under identical
conditions in the same experiment (Fig. 1).
Phenotype of Macs (2/2) Mice Expressing
the Double-Mutant MARCKS Protein
We have shown previously (Swierczynski et al., 1996)
that Macs (2/2) mice expressing the wild-type human
protein appeared to be completely normal, and that knock-
out mice expressing the single mutant (A2/G2) MARCKS
had about 75% perinatal mortality, were slightly smaller
than normal, but had phenotypically normal brains and
retinas, at least compared to the gross disruption of central
nervous system structures that characterize the Macs (2/2)
phenotype (Stumpo et al., 1995; Blackshear et al., 1997). We
attempted the same type of ‘‘rescue’’ experiment with the
transgenic mice expressing the double-mutant. When Macs
(2/2) mice expressed the double-mutant transgene at levels
comparable to or higher than the wild-type transgene that
was successful in rescuing the null phenotype, 100% of the
newborn mice also died at about the time of birth, as was
true of the original Macs (2/2) mice (Stumpo et al., 1995).
However, the double-mutant transgene expression ap-
peared to completely correct the gross anatomical abnor-
malities seen in the brains of the Macs (2/2) mice. As
shown in Fig. 2, the MARCKS knockout mice expressing
the double-mutant transgene had normal anterior cerebral
hemisphere fusion, normal forebrain commissures, includ-
ing the corpus callosum, and apparently normal lamination
patterns of the forebrain cortex. In particular, the severe and
widespread leptomeningeal neuronal ectopia characteristic
of the Macs (2/2) mice (Blackshear et al., 1997), reflected in
a grossly disordered pattern of outer cortical synaptophysin
staining, was not seen in the double-mutant-expressing
FIG. 1. Subcellular localization of wild-type and double-mutant
MARCKS in the neural tube at E9.5. Transgenic embryos ex-
pressing either wild-type (A) or double mutant (B) MARCKS
were prepared for frozen section immunohistochemistry with
the antibody to the epitope tag and a fluorescein-conjugated
second antibody. The control ( C ) was a nontransgenic embryo
of identical age. Each section was 10 mm in thickness, and is of
a portion of the cranial neural tube in each case. Film exposures
were identical (5 s) in each case; however, the developer expo-
sure in A was slightly longer than in B and C because of the
lower level of expression of the wild-type transgene. Other
controls in which each section was treated identically without
the primary antibody were completely negative for immunore-
activity (not shown). Bar, 10 mm.
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Macs (2/2) mice (Fig. 3). Finally, we have not seen either
exencephaly or omphalocele in the animals ‘‘rescued’’ by
the double-mutant transgene; both of these abnormalities
are common in the Macs (2/2) mice (Stumpo et al., 1995).
Thus, the cause of perinatal death in these animals is not
obviously due to a grossly disordered central nervous sys-
tem, as was presumed in the original knockout animals,
and remains unknown.
The retinas of the MARCKS-deficient mice exhibited an
interesting phenotype in that the normal lamination pat-
terns seen at the time of birth were disrupted (Stumpo et al.,
1995; see below). This characteristic phenotype included a
near absence of the normally well-demarcated, largely acel-
lular inner plexiform layer between the inner and outer
nuclear layers (see below). This phenotype was universal in
the MARCKS-deficient mice (Stumpo et al., 1995).
In the present studies, expression of the double-mutant
transgene restored this layer to its normal thickness (Figs. 2
and 4). However, this was accompanied by a new and
entirely unexpected phenotype: The appearance of ectopi-
cally located retinal tissue, generally in the vitreous humor
(Figs. 2 and 4). This abnormality was seen in all of the
double-mutant-expressing Macs (2/2) mice examined. In
other instances, extraocular retinal tissue and partially
duplicated retinas were found (data not shown). This con-
dition, which we will call ‘‘retinal ectopia,’’ ranged from
multiple, widespread deposits of retinal cells in the vitreous
humor, in many cases with rudimentary maintenance of
cell laminations (Figs. 4A and 4B), to a single instance of
abnormal retinal folding in one mouse (Fig. 4 I). The other
tissues of the eye, including the lens, optic nerve, skin over
the eye, etc. appeared to be normal except when disturbed
by the ectopically located retinal tissue (Fig. 4). In addition,
normal differentiation of retinal cells appeared to be
present, even in the ectopically located tissue (Fig. 4).
Because of these results, we examined retinas from eight
Macs (1/2) mice that expressed the transgene; these were all
normal (see also Fig. 5). We also reanalyzed retinal sections
from 35 of the original Macs (2/2) mice, i.e., without trans-
gene expression. Fifteen (43%) of these animals exhibited
similar retinal ectopia; this abnormality was readily discerned
as early as E12.5 (Fig. 6), before retinal cell differentiation
begins at about E13 (Young, 1983). Thus, a high frequency of
retinal ectopia appears to be part of the original MARCKS-
FIG. 2. Brain morphology of Macs (2/2) mice expressing the double-mutant transgene. Brains from mice at P0 were fixed in Bouin’s,
embedded in paraffin, sectioned at 5-mm intervals, and stained with hematoxylin and eosin. In A and B coronal sections through the anterior
forebrain of a Macs (2/2) mouse expressing the double-mutant transgene, a Macs (1/2) mouse expressing the double-mutant transgene
(C), and a Macs (2/2) mouse (D) are shown. Note the presence of the corpus callosum (arrows) in A–C but not in D. Note also the grossly
abnormal retinal morphology in A and B, but not in C. Bar, 20 mm.
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FIG. 3. Synaptophysin staining of brains from Macs (2/2) mice expressing the double- mutant transgene. Forebrains from mice at P0 were
fixed, embedded in paraffin, and cut into 5-mm sections and then immunostained with an antibody directed at synaptophysin, indicated by
the brown color. The blue counterstain is hematoxylin. Immunostained coronal sections through the outer layers of the forebrain cortex
are shown, with the intervertebral fissure (IVF) to the right in each case. A–C are from three Macs (2/2) mice expressing the double-mutant
transgene. D and H are from Macs (2/2) mice. E is from a Macs (1/2) mouse expressing the double-mutant transgene; F and G are adjacent
sections from a Macs (1/1) mouse, in which G was treated like F except for the absence of primary antibody. PM, pia mater; BL, basal
lamina; MZ, marginal zone; CP, cortical plate. Bar, 50 mm.
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deficiency phenotype. Remarkably, however, this was present
in 100% of the double-mutant-rescued knockout mice, de-
spite normalization of the other aspects of the phenotype,
including normal thickness of the inner plexiform layer, by
the expression of the double-mutant transgene.
Several additional studies were performed in an attempt to
determine the proximate cause of the retinal ectopia. At E9.5,
the optic vesicles in the knockout embryos appeared normal
histologically and by scanning electron microscopy; they also
displayed normal patterns of expression of chondroitin sulfate
proteoglycans and laminin (Blackshear et al., 1996). However,
profound abnormalities could be seen as early as E12.5 (Figs.
6J–6L), before significant retinal cell differentiation is present
in the mouse. In many cases, the eyes at E12.5 demonstrated
close juxtaposition between a portion of the retina and the
lens capsule (Figs. 6J–6L), raising the possibility of abnormal
FIG. 4. Retinal morphology of Macs (2/2) mice expressing the double-mutant transgene. Coronal sections of retinas of P0 mice are
shown, stained with hematoxylin and eosin. A–J are from Macs (2/2) mice expressing the double-mutant transgene; K is from a Macs (1/1)
mouse; and L is from a Macs (2/2) mouse. A and B are from the left and right retinas from a single mouse, as are C and D, E and F, G and
H, and I and J. Note the presence of the inner plexiform layer between the inner and outer nuclear layers in I–K, and the near absence of
this layer in L. Note also the widespread retinal ectopia in A–I, with only J appearing relatively normal among the Macs (2/2) mice
expressing the double- mutant transgene. Bar, 200 mm.
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adhesion between a portion of the retina and the lens as the
cause of the ectopia. No abnormalities in the expression of a
number of adhesion and matrix molecules were noted at that
stage, including chondroitin sulfate proteoglycans, phospha-
can, tenascin, or N-CAM (data not shown).
At later developmental stages, the impression of adhesion
between the retina and lens capsule was stronger, at E14.5
(Figs. 6F–6H) and E18.5 (Figs. 6B–6D). However, not all of the
abnormalities could be explained by continued adhesion be-
tween the lens and retina; for example, Fig. 6C shows a retinal
fold in what appears to otherwise be a normal retina, without
apparent lens adhesions. Such exuberant retinal growth could
be due to increased cell proliferation; however, staining for
proliferating cell nuclear antigen (Greenwell et al., 1991)
revealed no evidence for increased numbers of proliferating
cells in the retinas of the knockout mice (not shown).
In cases of the most extreme retinal disruption, as in Fig.
6D, retinal cells adhered to the lens capsule at many locations.
In such severe cases, a variety of retinal cells could be found in
the vitreous, including postmitotic cells staining for synapto-
physin, pyknotic nuclei and other cell debris, and even cells
from the pigment epithelium. We stained such abnormal
retinas for the presence of excess apoptosis, and for inflamma-
tory cells; however, the level of cellular apoptosis was similar
to that seen in control retinas, and no inflammatory cells were
present.
Normal Expression of MARCKS and MLP
in the Mouse Retina
These studies prompted us to evaluate the normal distri-
bution of MARCKS and MLP in the retina of mice during
development. As illustrated in Fig. 7B, MARCKS is very
highly expressed in all cells of the retina at E18.5 in the
normal fetal mouse, with particularly high-level expression
in the anuclear regions of the inner plexiform layer and the
optic nerve layer immediately adjacent to the vitreous
humor (Fig. 7B). Although MARCKS is also highly ex-
pressed in the cerebral cortex, the expression in the retina is
much greater at this date, as determined by comparative
immunostaining of these tissues in the same experiment
(Figs. 7A and 7B).
High-level expression of both MARCKS and MLP mRNA in
the retina has previously been demonstrated (Stumpo et al.,
1998). Retinal expression of the MARCKS transgene used in
these studies was also very high, as evidenced by expression of
a MARCKS-b-galactosidase transgene (Blackshear et al., 1996)
that used the same length of MACS promoter as that used in
the present experiments (Fig. 8). In similar studies using a
comparable MLP-b-galactosidase fusion protein (Stumpo et
al., 1998), retinal expression of the two fusion proteins was
very similar, with high level expression observed in essen-
tially all of the undifferentiated retinal cells and optic nerve at
E12.5, and high level expression in the inner plexiform layer,
the inner nuclear (ganglion cell) layer and optic nerve fiber
layer at E15.5 (Fig. 8).
DISCUSSION
In our previous attempts to perform structure–function
analysis of the MARCKS protein by the transgenic rescue of
MARCKS-deficient mice, we showed that expression of
epitope-tagged human MARCKS completely prevented the
FIG. 5. Retinal morphology in a Macs (2/2) mouse expressing the double-mutant transgene. Retinas from P0 mice are shown, stained
with hematoxylin and eosin. A is from a Macs (1/1) mouse; B is from a Macs (2/2) mouse; and C is from a Macs (1/2) mouse that
expressed the double-mutant transgene. Note the normal size of the inner plexiform layer (arrow) in A and C and its near absence in B, as
well as the absence of retinal ectopia in C. L, lens; V, vitreous humor; IN, inner nuclear layer; ON, outer nuclear layer; OP, optic nerve.
Bar 5 200 mm.
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severe neuroanatomical defects characteristic of the Macs
(2/2) phenotype (Swierczynski et al., 1996). In addition, we
showed that expression of a nonmyristoylatable form of the
protein, the A2/G2 mutant, could partially complement the
null phenotype: approximately 25% of the animals sur-
vived, and, although slightly smaller than normal, the
adults had anatomically normal brains and retinas (Swierc-
zynski et al., 1996).
The present studies extend these results by attempting to
complement the null phenotype with the transgenic expres-
sion of the double-mutant MARCKS. This mutation has
been shown previously to result in a protein that exhibits
negligible affinity for fibroblast membranes in a cell-free
assay, compared to avid binding of the wild-type protein
(Swierczynski and Blackshear, 1995). Similarly, when wild-
type and mutant human MARCKS were expressed in REF52
rat fibroblasts, only 0.8% of the double-mutant protein was
found bound to a crude cell membrane fraction, compared
to 82% of the wild-type protein (Swierczynski and Blacks-
hear, 1996). Very similar data were obtained when chicken
MARCKS was expressed in human 293 cells: About 80% of
the wild-type protein was associated with the membranes,
compared to 2% of the double-mutant protein. The plasma
membrane localization of the wild-type protein was con-
firmed by immunoelectron microscopy (Swierczynski and
Blackshear, 1996).
Based on the data from these previous studies, we ex-
pected the double-mutant form of MARCKS to have negli-
gible affinity for membranes when expressed in intact mice.
At least in mouse brain, this did not seem to be the case. For
example, simple fractionation of brain into crude mem-
brane and cytosolic fractions by high-speed centrifugation
revealed that about 55% of the double-mutant protein was
found in the membrane fraction compared to 92% of the
wild-type protein. Similarly, immunohistochemical stain-
ing of the neural tube at E9.5, when MARCKS staining of
plasma membranes can be clearly visualized (Blackshear et
al., 1997), showed that the double-mutant protein was
expressed to a greater extent in the cytosol than the
wild-type endogenous protein, but a substantial fraction of
the protein still appeared to be associated with the plasma
membrane. In contrast to the previous experiments in
stable cell lines, therefore, the double-mutant protein still
was capable of appreciable plasma membrane association in
the neural tube and brain of intact animals. One interesting
possibility raised by these results is that, when double-
mutant MARCKS is expressed under more physiological
conditions than in the cultured cell studies, i.e., in the cell
types in intact tissues that normally express high levels of
the protein and in which it is critical for normal develop-
ment, other mechanisms of maintaining membrane asso-
ciation may be operative. These could include continued
binding to the lipid bilayer mediated by other domains of
the protein, or perhaps interactions with other membrane
or cortical proteins that persist despite the presence of the
two mutations.
These results may help to explain the rather surprising
FIG. 7. Endogenous MARCKS expression in fetal mouse retina.
Tissues from a Macs (1/1) mouse at E18.5 were fixed and
embedded in paraffin, and immunostained for endogenous
mouse MARCKS. The three tissues shown are outer forebrain
cerebral cortex (A), retina (B), and the cartilage primordium of
the presphenoid bone (C). The light color indicates antibody
staining (fluorescence). In all three cases, photographic exposure
was the same (15 s), and developer exposure was the same. Since
all three tissues were stained in parallel, the amount of fluores-
cence shown is directly proportional to the amount of MARCKS
expressed in the tissue. In A, cp, cortical plate; mz, marginal
zone; bl, basal lamina; pm, pia mater. In B, onl, outer nuclear
layer; inl, inner nuclear layer; arrow, inner plexiform layer; v,
vitreous humor. In C, the arrow points to a thin layer of surface
cells that are MARCKS positive in the otherwise negative
cartilage. Bar, 25 mm.
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finding that this double-mutant protein was able to comple-
ment many of the anatomical defects in the brain that
characterize the Macs (2/2) phenotype. The following
abnormalities were corrected: exencephaly; omphalocele;
agenesis of the corpus callosum and other forebrain com-
missures; neuronal leptomeningeal ectopia, with grossly
aberrant synaptophysin staining; and near absence of the
inner plexiform layer of the retina. Despite these anatomi-
cal corrections, the double-mutant-expressing knockout
mice had a 100% perinatal mortality. It is possible that this
universal mortality resulted from a defect in MARCKS
signaling due to its unvarying, pseudo-phosphorylated
state. Experiments are currently in progress in which ex-
pression of the normally myristoylated tetra-asp and tetra-
asn proteins is used to complement the null phenotype;
these studies may help to answer the question about the
PKC-dependent signaling function of the protein. However,
it is clear that the simple presence of normal MARCKS
sequences in the knockout mice is not by itself sufficient to
complement the null phenotype, since transgenic expres-
sion of wild-type MARCKS linked to b-galactosidase in a
fusion protein does not complement any of the Macs (2/2)
phenotypic abnormalities, despite abundant expression
(W. S. Lai and P. J. Blackshear, unpublished data).
Since all of the cerebral anatomical abnormalities of the
MARCKS-deficient mice were corrected in the knockout
mice expressing the double-mutant transgene, we were
surprised to note the presence of a new phenotype in 100%
of these animals: retinal ectopia. This striking abnormality
varied from simple and apparently single retinal folds to
widespread vitreous fragments of retinal tissue to extraocu-
lar retina development, despite the apparent normalization
of the thickness of the inner plexiform layer in the same
eyes. This abnormality has not been seen in any of the Macs
(1/1) or (1/2) mice analyzed, nor was it present in the
transgenic mice expressing the double-mutant protein on a
Macs (1/1) or (1/2) background. Similar abnormalities
have been found in association with microphthalmia,
which can occur in as many as 4–10% of C57BL mice
(Smith et al., 1994); similarly, mice in which lens formation
FIG. 8. MARCKS-b-galactosidase and MLP-b-galactosidase fusion protein expression in transgenic fetal mouse retinas. Patterns of retinal
MARCKS- and MLP-b-galactosidase expression were evaluated in fetal transgenic mice, with the blue color indicating b-galactosidase
staining, and the pink color the fast-red counterstain. A, MARCKS-b-galactosidase staining at E12.5; B, MARCKS-b-galactosidase staining
at E15.5; C, MLP-b-galactosidase staining at E12.5; D, MLP-b-galactosidase staining at E15.5. In A and C, the retinal cells are
undifferentiated and uniformly and heavily stained, as is the optic nerve. In B and D, the inner plexiform layer, the outer nuclear (ganglion
cell) layer and the optic nerve fiber layer are all more heavily stained than the outer nuclear (ventricular cell) layer.
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has been disrupted by mutation or retinal expression of a
toxin also exhibited retinal folding and other retinal abnor-
malities (Zwan and Webster, 1984; Landel et al., 1988;
Breitman et al., 1989). However, both eye size and lens
development appeared remarkably normal in the present
studies, even when the retina was grossly disordered.
These results prompted us to reexamine the retinal
morphology of the Macs (2/2) mice, in which we had
previously described the only retinal abnormality as a
near-absence of the inner plexiform layer (Stumpo et al.,
1995). By examining many sections of eyes from these mice,
we found a frequency of retinal ectopia of about 43% (15 of
35 mice examined). In general, this appeared to be less
severe than the universal ectopia observed in the double-
mutant rescued mice described here. However, occasional
instances of more severe ectopia, including vitreous retinal
‘‘islands,’’ as well as extraocular and partially duplicated
retina, were observed in a few of the animals. We found
clear instances of this abnormality in mice as early as E12.5,
before any retinal cell differentiation occurs (Young, 1983);
in addition, the appearance of the retinal cells, and their
state of differentiation, appeared to be normal, despite their
ectopic locations. Thus, it seems unlikely that this abnor-
mality is due to either retinal cell differentiation or migra-
tion, since both appeared to be occurring normally in
unaffected areas, and as normally as possible in affected
areas. Instead, it appears that the abnormality is due to an
error early in eye development. The many instances of
incomplete separation of the retina and lens suggest the
possibility that the lens pit and neural layer of the optic cup
fail to separate normally at E9–11 (Kaufman, 1979), a time
when both MARCKS (Blackshear et al., 1997) and MLP (Wu
et al., 1996; Chen et al., 1996; Stumpo et al., 1998) are
highly expressed in the developing neural tube.
How can we explain the effects of an expressed mutant
transgene that simultaneously corrects most of the abnor-
malities characteristic of the Macs (2/2) phenotype, while
apparently making worse a single aspect of the phenotype?
One possibility is that the double-mutant form of the
protein is exerting a dominant-negative effect on normal
compensatory expression of the MARCKS homologue, the
MARCKS-like protein or MLP. This speculation is sup-
ported by several indirect lines of evidence. First, MLP is
very highly expressed in the brain and retina of fetal mice,
and is highly expressed in the neural tube from about E8
onward (Stumpo et al., 1995; Wu et al., 1996; Chen et al.,
1996; Stumpo et al., 1998). In addition, the expression
patterns of MARCKS and MLP in the developing retina are
very similar, as shown here, with high-level expression of
both proteins in essentially all of the undifferentiated
retinal cells at E12.5. Previous studies with mutant forms of
MLP, which lacked a phosphorylation site domain, have
suggested that the mutant could exert dominant-negative
influences on macrophage behaviors such as phagocytosis
(Zhu et al., 1995; Li et al., 1996). We showed by compara-
tive immunohistochemistry in the present work that
MARCKS is very highly expressed in the retina compared to
the next greatest site of expression, the forebrain cortex.
Since the double-mutant transgene is driven by normal
MARCKS promoter elements and is very highly expressed
in the retina (Stumpo et al., 1998; this paper), it is possible
that in this tissue the transgenic protein is exerting a
dominant-negative effect by interfering with the action of
other ‘‘MARCKS equivalents,’’ represented in this case by
MLP. The effects of Mlp knockout on the retina were not
commented on in one report, in which the mice exhibited
universal exencephaly (Chen et al., 1996); in another report,
survival to adulthood without neural tube defects was fairly
common, and the retinal morphology of these surviving
mice was described as ‘‘thinner and compressed . . . , al-
though the overall layered structure was not altered’’ (Wu et
al., 1996). If the apparent deleterious effects of the double-
mutant protein on the retina seen in the present study are
due to a dominant-negative effect of the mutant protein,
this would predict that a MARCKS/MLP double knockout
would have universal and perhaps severe retinal ectopia.
However, since these animals are likely to have very severe
defects in neural tube formation and perhaps universal
exencephaly, it may be difficult to determine the effect of
this double knockout on retinal development.
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